because a similar link between BV and prematurity has been established in women without these risk factors for preterm birth.
The mechanism by which BV causes preterm delivery or low birth weight (LBW) is not known. However, a substantial body of data demonstrates a link between BV and upper-genital-tract infection in pregnancy, including histologic chorioamnionitis, 7 infection of the chorioamnion, 7 and amnioticfluid infection, s'8 '9 These infections are common complications of preterm delivery and predictors of higher neonatal morbidity. BV has also been linked with an increased risk of postcesarean endometritis. 9 If BV or other infectious morbidity represents a preventable cause of preterm birth, the screening and treatment of women with this syndrome would prevent the health care costs associated with these perinatal complications. The present study was 12 In addition, BV in pregnant women is associated with amniotic-fluid infection and postpartum endometritis and their attendant costs. Table summarizes the results of our literature search for the strength of association between BV and each of these perinatal complications. -6'8'9'3'4 The annual frequency of the diagnosis of these perinatal complications in the U.S. pregnant population and the proportion of each complication that might be attributed to BV are presented in Table 2 24, 25 If the effectiveness rate assumption for these treatments is 65% and effective treatment decreases the frequency of preterm delivery attributable to BV by 50%, 24 then a conservative estimate of potential cost savings, after accounting for the costs of screening and treatment, would be $150 million annually.
The mounting body of evidence linking BV to pregnancy complications worldwide, combined with the excess financial and emotional costs associated with prematurity, suggest several research areas that deserve attention. First, the optimal time for screening and treatment has not been defined, although at least 2 studies suggest that early screening in the first or second trimester may be more predictive of preterm delivery than later screening. 4'5 This finding should be verified in a systematic way in other populations. Second, economic parameters need to be applied to the results of recently completed randomized treatment trials demonstrating the effect of drug therapy for BV during pregnancy in the prevention of pregnancy complications. 24'26 If these regimens are shown to decrease the incidence of pregnancy complications associated with BV, it will be possible to show the cost savings accruing to the health care payers.
Physicians are urged to learn to recognize the clinical signs of BV (milky vaginal discharge, a vaginal pI-I >4.5, and the release of an amine odor after the addition of 10% potassium hydroxide to the vaginal fluid), to screen selected patients, and to follow recommended treatment guidelines. Ultimately, it is hoped that the appropriate treatment of BV in pregnant women will be a cost-effective approach to reducing the incidence of preterm labor and the delivery of LBW infants.
